¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"solid basal cell carcinoma"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • continuous cell line
    ¹«ÇÑÁõ½Ä¼¼Æ÷ÁÖ, ¿¬¼Ó°è´ë¼¼Æ÷ÁÖ
  • contractile fiber cell
    ¼öÃ༶À¯¼¼Æ÷
  • cover cell
    µ¤°³¼¼Æ÷
  • crenated cell
    Åé´ÏÀûÇ÷±¸
  • crescent cell anemia
    Ãʽ´ÞÀûÇ÷±¸ºóÇ÷
  • crypt cell
    âÀÚ»ù¼¼Æ÷, ¿ò¼¼Æ÷
  • cuboidal cell
    ÀԹ漼Æ÷, ÁÖ»çÀ§¼¼Æ÷
  • cylindrical cell
    ¿øÁÖ¼¼Æ÷
  • cytotoxic cell
    ¼¼Æ÷µ¶¼º¼¼Æ÷
  • cytotoxic cell protein
    ¼¼Æ÷µ¶¼º¼¼Æ÷´Ü¹éÁú
  • cytotoxic killer T cell
    ¼¼Æ÷µ¶¼º»ìÇØT¼¼Æ÷
  • cell
    ¼¼Æ÷
  • cell adhesion molecule
    ¼¼Æ÷ºÎÂøºÐÀÚ
  • cell agar plate
    ¼¼Æ÷¿ì¹«ÆòÆÇ
  • cell bank
    ¼¼Æ÷ÀºÇà
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • cell division
    ¼¼Æ÷ºÐ¿­
  • cell envelope
    ¼¼Æ÷²®Áú
  • cell fusion
    ¼¼Æ÷À¶ÇÕ
  • cell hybridization
    ¼¼Æ÷ºÎÇÕÈ­, ¼¼Æ÷ÇÏÀ̺긮µåÈ­
  • cell inclusion
    ¼¼Æ÷Æ÷ÇÔ¹°
  • cell interaction
    ¼¼Æ÷»óÈ£ÀÛ¿ë
  • cell lethality
    ¼¼Æ÷Ä¡»çÀ²
  • cell line
    ¼¼Æ÷°è, ¼¼Æ÷ÁÖ
  • cell loss
    ¼¼Æ÷¼Ò½Ç
  • cell mass
    ¼¼Æ÷µ¢ÀÌ
  • cell membrane
    ¼¼Æ÷¸·
  • cell organelle
    ¼¼Æ÷¼Ò±â°ü
  • cell respiration
    ¼¼Æ÷È£Èí
  • cell strain
    ¼¼Æ÷ÁÖ
  • cell substitution
    ¼¼Æ÷´ëÄ¡, Ç÷±¸´ëÄ¡
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • antibody forming cell
    Ç×ü»ý»ê¼¼Æ÷(ù÷ô÷ßæß§á¬øà).
  • antibody producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antigen presenting cell
    Ç׿øÁ¦½Ã¼¼Æ÷.
  • antigen reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷.
  • apex of cell
    ¼¼Æ÷²À´ë±â
  • apical cell
    Á¤(´Ü)¼¼Æ÷(ð¢Ó®á¬øà)
  • argentaffin chromaffin cell
    Å©·Òģȭ¼º ¼¼Æ÷
  • argyrophil(e) cell
    ÀºÄ£È­¼º ¼¼Æ÷(ëÞöÑûúàõá¬øà)
  • arteritis,giant cell of aorta
    ´ëµ¿¸Æ(ÓÞÔÑØæ)ÀÇ °Å¼¼Æ÷¼º(ËÝá¬øààõ)
  • free cell
    ÀÚÀ¯¼¼Æ÷(í»ë¦á¬øà).
  • functional cell
    ±â´É¼¼Æ÷(ѦÒöá¬øà).
  • funicular cell
    ÁÙ¼¼Æ÷, »è¼¼Æ÷(ßãá¬øà).
  • fusiform cell
    ¹æÃß¼¼Æ÷
  • fusiform endothelial cell
    ¹æÃß³»ÇǼ¼Æ÷
  • fusiform myoepithelial cell
    ¹æÃßÇü ±Ù»óÇÇ ¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • lateral basal brach
    °¡Âʹٴڰ¡Áö
  • lateral basal branch
    °¡Âʹٴڰ¡Áö
  • lateral basal segment
    °¡Âʹٴڱ¸¿ª
  • lateral basal segmental artery
  • lateral basal segmental bronchus
    °¡Âʹٴڱ¸¿ª±â°üÁö
  • lateral basal vein
  • medial basal branch
    ¾ÈÂʹٴڰ¡Áö
  • medial basal segment
    ¾ÈÂʹٴڱ¸¿ª
  • medial basal segmental bronchus
    ³»ÃøÆóÀúÁö(Ò®ö°øËî¼ò«).
  • medial basal segmental bronchus
    ¾ÈÂʹٴڱ¸¿ª±â°üÁö
  • plate, basal
    ±âÀúÆÇ (Æí¸ðÀÇ)
  • point of basal convergence
    ±âÃÊÆøÁÖÁ¡(Ðñõ¨ÜßñÍïÇ).
  • posterior basal branch
    µÚ¹Ù´Ú°¡Áö
  • posterior basal segment
    µÚ¹Ù´Ú±¸¿ª
  • posterior basal segmental bronchus
    µÚ¹Ù´Ú±¸¿ª±â°üÁö, ÈÄÆóÀúÁö(ý­øËî¼ò«).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • Dark cell
    ¾îµÎ¿î¼¼Æ÷
    [¿¾ ¿ë¾î] ¾ÏÁÖ¼¼Æ÷
  • Trophoblastic giant cell
    ¿µ¾ç¸·°Å´ë¼¼Æ÷
    [¿¾ ¿ë¾î] °Å´ë¿µ¾ç¸·¼¼Æ÷
  • Primordial germ cell
    ¿ø½ÃÁ¾ÀÚ¼¼Æ÷
    [¿¾ ¿ë¾î] ¿ø±âÁ¾(¹è)¼¼Æ÷
  • Primordial germ cell
    ¿ø½ÃÁ¾ÀÚ¼¼Æ÷
    [¿¾ ¿ë¾î] ¿ø±âÁ¾¼¼Æ÷
  • Primordial germ cell
    ¿ø½ÃÁ¾ÀÚ¼¼Æ÷
    [¿¾ ¿ë¾î] ¿ø½ÃÁ¾ÀÚ¼¼Æ÷
  • Columnar ependymal cell
    ¿øÁÖ³ú½Ç¸·¼¼Æ÷
    [¿¾ ¿ë¾î] ¿øÁÖ»óÀǼ¼Æ÷
  • Columnar epithelial cell
    ¿øÁÖ»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ¿øÁÖ»óÇǼ¼Æ÷
  • Columnar cell
    ¿øÁÖ¼¼Æ÷
    [¿¾ ¿ë¾î] ¿øÁÖ¼¼Æ÷
  • Type II hair cell
    ¿øÁÖÅм¼Æ÷
    [¿¾ ¿ë¾î] ÀüÆÄ¿¬Á¢¼¼Æ÷
  • Secretory cell of pyloric gland
    À§³¯¹®»ù¼¼Æ÷
    [¿¾ ¿ë¾î] À¯¹®¼±¼¼Æ÷
  • Secretory cell of cardiac gland
    À§µé¹®»ù¼¼Æ÷
    [¿¾ ¿ë¾î] ºÐ¹®¼±¼¼Æ÷
  • Gastrointestinal endocrine cell
    À§Ã¢ÀÚ³»ºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] À§Ã¢ÀÚ³»ºÐºñ¼¼Æ÷
  • Synovial cell
    À±È°¼¼Æ÷
    [¿¾ ¿ë¾î] Ȱ¸·¼¼Æ÷
  • Principal cell
    À¸¶ä¼¼Æ÷
    [¿¾ ¿ë¾î] ÁÖ¼¼Æ÷
  • Pancreatic endocrine cell
    ÀÌÀÚ³»ºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] ÃéÀå³»ºÐºñ¼¼Æ÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 11
OSCC oral squamous cell carcinoma
PCA para-chloramphetamine; parietal cell antibody; passive cutaneous anaphylaxis; patient care assistant...
PHC personal health costs; posthospital care; premolar hypodontia, hyperhidrosis, [premature] canities [...
RCCP renal cell carcinoma, papillary
SCCB small-cell carcinoma of the bronchus
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 11
LCNEC Large cell neuroendocrine carcinoma
MCC Merkel Cell Carcinoma
MRCC Metastatic renal cell carcinoma
OSCC Oral squamous cell carcinoma
RCC Renal Cell Carcinoma
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • blood cell counter
    Ç÷±¸ °è¼ö±â
  • bone cell
    °ñ ¼¼Æ÷
    °ñÁ¶Á÷ÀÇ ±âº» ¼¼Æ÷. °ñ Á¶Á÷¿¡´Â µüµüÇÑ °ñ ±âÁú¾È¿¡ °ñ¼Ò°­À̶ó°í ÇÏ´Â Æ´ÀÌ ±ºµ¥±ºµ¥ ÀÖ°í, ±× ¼Ó¿¡ 1°³¾¿ÀÇ °ñ ¼¼Æ÷°¡ µé¾î ÀÖ´Ù. °ñ ¼¼Æ÷ÀÇ ÇüÅ´ °ñ¼Ò°­°ú ÀÏÄ¡ÇÏ¿© ÆíÆòÇÑ Å¸¿øÇüÀ¸·Î, ±æÀÌ´Â 15¡­27 ¥ìmÀÌ´Ù. °ñ ¼¼Æ÷´Â ´Ù¼öÀÇ °¡´Â ¿øÇüÁú µ¹±â°¡ À־, À̰ÍÀÌ ±âÁú ³»ÀÇ °ñ ¼¼°üÀ» ÅëÇÏ¿© °¡±îÀÌ ÀÖ´Â °ñ ¼¼Æ÷ÀÇ µ¹±â¿Í ÇÕÄ£´Ù. °ñ ¼¼Æ÷´Â º»·¡ °áÇÕÁ¶Á÷ÀÇ ¼¶À¯¾Æ¼¼Æ÷¿¡¼­ Çü¼ºµÇ´Â °ÍÀ¸·Î, ¸ÕÀú °ñ¾Æ¼¼Æ÷°¡ µÇ¾î, À̰ÍÀÌ ±âÁúÀ» ¸¸µé°í ÀÚ½ÅÀº ±× ±âÁú ¼Ó¿¡ µé¾î°¡ °ñ¼¼Æ÷·Î µÈ´Ù. À̰ÍÀº °ñ Á¶Á÷ÀÇ Á¦Á¶ÀÚÀ̸ç, ¼¼Æ÷ÁúÀº ¹Ì·®ÀÇ ¹ÌÅäÄܵ帮¾Æ¸¦ Æ÷ÇÔÇϰí, È£¾à¿°±â¼ºÀ» ³ªÅ¸³½´Ù.
  • bone marrow cell
    °ñ¼ö ¼¼Æ÷
  • bristle cell
    °­¸ð ¼¼Æ÷, ¸ð¼¼Æ÷
  • calcigerous cell
    ¼®È¸È­ ¼¼Æ÷
  • cameloid cell
    Ÿ¿øÇü ÀûÇ÷±¸
  • cancer cell
    ¾Ï ¼¼Æ÷
    Á¤»óÀÎ Á¶Á÷ ¼¼Æ÷°¡ ¾î¶² ¿øÀÎÀ¸·Î ¹«Á¦ÇÑ Áõ½ÄÇÏ¿© ±× »ýüÀÇ »ýȰÇö»óÀ̳ª ÁÖÀ§ÀÇ Á¶Á÷ »óÅ µî¿¡ °ü°è¾øÀÌ ±Þ¼ÓÇÑ ¹ßÀ°À» °è¼ÓÇÏ¿© ¸¶Ä§³»´Â »ý¸íÀ» ²÷°Ô ÇÏ´Â ¾Ç¼ºÀÇ ½Å»ý¹°À̶ó°íµµ º¼ ¼ö ÀÖ´Â ¼¼Æ÷. ¼¼Æ÷ÇÐÀûÀ¸·Î º¸¸é ±× ¸ð¾çÀ̳ª Å©±â°¡ Á¤»ó ¼¼Æ÷¿¡ ºñÇÏ¿© ´Ù¼Ò º¯È­µÇ¾î ÀÖ´Ù. Áï, ÇÙÀº ¿°»öü°¡ ¸¹°í, ÇÙÀÇ ¿øÇüÁú¿¡ ´ëÇÑ ºñ°¡ Å©¸ç, ÇÙ¼Òü¸¦ °¡Áö°í, ÀÚÁÖ ÇÙ ºÐ¿­»óÀ» ³ªÅ¸³½´Ù. À̰ÍÀ» ÀÌÇü¼ºÀ̶ó°í ÇÑ´Ù. ÀÌÇü¼ºÀÌ °­ÇÑ °ÍÀÌ ¾Ï ¼¼Æ÷ÀÇ Æ¯Â¡ÀÌ´Ù. À̰ÍÀ» ÀÌ¿ëÇÑ °ÍÀÌ ¼¼Æ÷ÁøÀ̸ç, À§¾Ï µî ¸ðµç ¾ÏÀÇ Á¶±â Áø´Ü¿¡ Å« ¿ªÇÒÀ» Çϰí ÀÖ´Ù. Á¤»ó ¼¼Æ÷°¡ ¾î¶»°Ô ÇØ¼­ ¾Ï ¼¼Æ÷·Î º¯Çϴ°¡´Â ºÒ¸í·áÇÑ Á¡ÀÌ ¸¹Áö¸¸, È÷¸£È¿ÀÇ Àڱؼ³Àº À¯¸íÇÏ´Ù. À̰ÍÀº È­ÇÐÀû, ±â°èÀû, ¹°¸®Àû µîÀÇ ¸¸¼º ÀÚ±ØÀÌ ÀÛ¿ëÇÏ´Â °÷¿¡ ¾ÏÀÌ ¹ß»ýÇÑ´Ù´Â ¼³ÀÌ´Ù. ¹ÙÀÌ·¯½º¿ÍÀÇ °ü°èµµ ±Ù³â¿¡ ÁÖ¸ñÀ» ²ø¾î, F.P. ¶ó¿ì½ºÀÇ ´ßÀÇ À°Á¾ ¹ÙÀÌ·¯½º³ª R.E. ¼îÇÁÀÇ Åä³¢ÀÇ À¯µÎÁ¾ ¹ÙÀÌ·¯½º´Â À¯¸íÇÏÁö¸¸, Àΰ£ÀÇ ¾Ï°ú È®½ÇÇÏ°Ô °ü°è¸¦ °®´Â ¹ÙÀÌ·¯½º´Â ¾ÆÁ÷ ¹ß°ßÇÏÁö ¸øÇϰí ÀÖ´Ù. ¾Ï ¼¼Æ÷°¡ Á¤»ó ¼¼Æ÷¿Í ´Ù¸¥ Á¡Àº ÀÚÀ²ÀûÀ¸·Î Áõ½ÄÇϰí ÁÖÀ§ÀÇ Á¶Á÷À» ÆÄ±«ÇÏ¿© ħÀ±¼ºÀ¸·Î ¹ßÀ°ÇÏ´Â °Í, ¾Ï ¼¼Æ÷°¡ À¯¸®µÇ¾î ¸²ÇÁÇ༺, Ç÷Ç༺À¸·Î ¿ø°Ý Àå±â¿¡ ÀüÀÌÇÏ´Â °Í, ÆÄÁ¾À̶ó ÇÏ¿© º¹°­³»³ª Èä°­³»ÀÇ Àå±âÀÇ ¾Ï¿¡¼­´Â ¾Ï ¼¼Æ÷°¡ À帷¿¡ µµ´ÞÇÏ¸é º¹¸·À̳ª È丷¿¡ ºÎÂøÇÏ¿© ¹ßÀ°À» °è¼ÓÇÏ´Â °Í µîÀÌ´Ù. ÀÌ·± Ư¼º ¶§¹®¿¡ ¾ÏÀÇ Ä¡·á°¡ º¹ÀâÇØÁö°í Àç¹ßµÇ±â ½±´Ù. µû¶ó¼­ ¾ÏÀ» °íÄ¡·Á¸é ¾Ï ¼¼Æ÷°¡ ÀÌ·± Ư¼ºÀ» ÃæºÐÈ÷ ¹ßÈÖÇÏÁö ¸øÇÏ´Â Á¶±â¿¡ ¹ß°ß, Ä¡·áÇØ¾ß ÇÑ´Ù.
  • capsule cell
    ÇǸ· ¼¼Æ÷, À§¼º ¼¼Æ÷
  • caterpillar cell
    ¸ðÃæ ¼¼Æ÷
  • caveolated cell
    ¼ÒÆ÷¿ò ¼¼Æ÷
    ÈçÈ÷ º¼ ¼ö ÀÖ´Â °ÍÀº ¾Æ´ÏÁö¸¸, ¼ÒÀå, ´ëÀå, À§ µîÀÇ ¿ò°ú À¶¸ð¿¡¼­ º¼ ¼ö ÀÖ´Ù. ²À´ë±âº¸´Ù ¹Ù´Ú ºÎºÐÀÌ ³ÐÀ¸¸ç ²À´ë±â¿¡´Â ¹Ì¼¼ À¶¸ð°¡ Àִµ¥ ±× ¼Ó¿¡´Â ¼¼»ç ´Ù¹ßÀÌ ÇÔÀ¯µÇ¾î ÀÖÀ¸¸ç, ÀÌµé ¼¼»ç ´Ù¹ß »çÀÌ¿¡ ¼¼Æ÷¸·ÀÌ ÇÔÀÔµÈ ¼Ò¿òµéÀÌ ÀÖ´Ù.
  • cell
    ¼¼Æ÷, ¹úÁý, ºÀ¼Ò
    1. »ýü Á¶Á÷ÀÇ ±âº» ´ÜÀ§. Çö¹Ì°æÀ¸·Î °üÂûÀÌ °¡´ÉÇÑ À¯±âü¸¦ ±¸¼ºÇÏ´Â ´Ù¾çÇÑ ¿øÇüÁú µ¢¾î¸® Áß ÇÑ °¡Áö. °¢ ¼¼Æ÷´Â ¼¼Æ÷¸·, ¿øÇüÁú, ÇÙ, ´Ù¾çÇÑ ºÀÀÔü¸¦ °¡Áö°í ÀÖ´Ù. °¢ ¼¼Æ÷ Á¾·ù´Â °¢°¢ÀÇ ´ë»ç ¿ä±¸, ÀÛ¿ë, Åõ°úµµ, ´Ù¸¥ ¼¼Æ÷·Î ºÐÈ­ÇÏ´Â ´É·Â, Àç»ý»ê¼º°ú ¼ö¸íÀ» °¡Áø »ì¾Æ ÀÖ´Â ´ÜÀ§ÀÌ´Ù. 2. »ý¹°ÀÇ ¸öÀ» ±¸¼ºÇÏ´Â ÃÖ¼ÒÀÇ ´ÜÀ§. ¸¹Àº »ý¹°Àº ´Ù¼öÀÇ ¼¼Æ÷·Î ÀÌ·ç¾îÁ® Àֱ⠶§¹®¿¡ ´Ù¼¼Æ÷ »ý¹°À̶ó°í ÇÏÁö¸¸, ¾î¶² Á¾¿¡¼­´Â ±× ÀÚü°¡ ÇϳªÀÇ ¼¼Æ÷·Î µÇ¾î Àֱ⠶§¹®¿¡ ´Ü¼¼Æ÷»ý¹°À̶ó ÇÑ´Ù. ¼¼±Õ, ±ÔÁ¶, ¹Ý´Þ¸», Ŭ·Î·¼¶ó¿Í °°Àº °£´ÜÇÑ Á¶·ù, ¾Æ¸Þ¹Ù, ¤½Å¹ú·¹¿Í °°Àº ¿ø»ýµ¿¹° µîÀº ´Ü¼¼Æ÷»ý¹°ÀÌ´Ù. º¸Åë µ¿¹°ÀÇ ³­ÀÚ´Â ¹ß»ý Ãʱ⿡´Â ´Ü¼¼Æ÷ÀÌÁö¸¸, °ð ºÐ¿­ÇÏ¿© ´Ù¼¼Æ÷·Î µÈ´Ù. ´«À¸·Î º¸ÀÌ´Â °Í¿¡´Â ¹ß»ý ÃʱâÀÇ µ¿¹°ÀÇ ³­ÀÚ, ½Å°æ¼¼Æ÷
  • cell adhesion molecular deficiency
    ¼¼Æ÷ À¯Âø ºÐÀÚ °áÇÌ
  • cell adhesive matrix assay
    ¼¼Æ÷ Á¡Âø ±âÁú ºÐ¼®
  • cell axon terminal
    ¼¼Æ÷ Ãà»è Á¾¸»
  • cell bound antibody
    ¼¼Æ÷ °áÇÕ Ç×ü
    Ç×ü´Â Fc ºÎÀ§¸¦ °³Àç½ÃÄÑ ¼¼Æ÷ÀÇ Fc ¼ö¿ë±â¿Í °áÇÕÇϴµ¥ ÀϹÝÀûÀ¸·Î ´Üüº¸´Ùµµ ÁßÇÕüÀÎ ÆíÀÌ ¼¼Æ÷¿¡ ´ëÇÑ Ä£È­¼ºÀÌ ³ô¾ÆÁø´Ù. ½ÇÁ¦ÀÇ °áÇÕ ´É·ÂÀº ¸é¿ª ±Û·ÎºÎ¸° class »çÀÌ¿¡¼­ ÇöÀúÇÑ Â÷À̸¦ º¸°Ô µÇ´Âµ¥ ¼¼Æ÷°¡ ´Ù¸£¸é °¢°¢¿¡ ´ëÇÑ Ä£È­¼ºÀÌ º¯È­Çϰí Ç×ü¿Í ¼¼Æ÷ ¾çÂÊÀÇ ¼ºÁúÀÌ °ü¿©ÇÏ´Â °ÍÀ¸·Î »ý°¢µÇ¾î ÀÖ´Ù. ´Üü Áß¿¡¼­µµ IgE³ª ¼³Ä¡·ù µ¿¹°ÀÇ IgG´Â µ¿Á¾ ģȭ¼º Ç×ü¶ó°í ºÒ¸®¿ì¸ç ¾Ë·¹¸£±â³ª ¾Æ³ªÇʶô½Ã½º ¹ÝÀÀÀÇ ±âÀÎÀÌ µÈ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
carcinoma, lewis lung A carcinoma discovered by dr. Margaret r. Lewis of the wistar institute in 1951. This tumour originated spontaneously as a carcinoma of the lung of a c57bl mouse. The tumour does not appear to be grossly haemorrhagic and the majority of the tumour tissue is a semifirm homogeneous mass. It is also called 3ll and llc and is used as a transplantable malignancy.
(12 Dec 1998)
carcinoma, lobular A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumours in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces.
(12 Dec 1998)
carcinoma, medullary A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies.
(12 Dec 1998)
carcinoma, mucoepidermoid A tumour of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumours of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumour of the parotid.
(12 Dec 1998)
carcinoma myxomatodes An obsolete term for a form of colloid cancer in which there is myxomatous metaplasia of the cellular fibrous stroma.
(05 Mar 2000)
carcinoma, neuroendocrine A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumours include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, merkel cell tumour, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumours, and pheochromocytoma. Neurosecretory granules are found within the tumour cells.
(12 Dec 1998)
carcinoma, papillary A malignant neoplasm characterised by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells.
(12 Dec 1998)
carcinoma, papillary, follicular A thyroid neoplasm of mixed papillary and follicular arrangement. Its biological behaviour and prognosis is the same as that of a papillary adenocarcinoma of the thyroid.
(12 Dec 1998)
carcinoma simplex An obsolete term for any form of carcinoma in which the relative proportions of stroma and neoplastic epithelial cells are not unusual, i.e., stromal elements are not comparatively abundant, nor are they reduced in amount or lacking; an obsolete term for a carcinoma lacking any identifiable microscopic pattern, such as glandular structure.
(05 Mar 2000)
carcinoma, skin appendage A malignant tumour of the skin appendages, which include the hair, nails, sebaceous glands, sweat glands, and the mammary glands.
(12 Dec 1998)
carcinoma, verrucous A variant of well-differentiated epidermoid carcinoma that is most common in the oral cavity, but also occurs in the larynx, nasal cavity, oesophagus, penis, anorectal region, vulva, vagina, uterine cervix, and skin, especially on the sole of the foot. Most intraoral cases occur in elderly male abusers of smokeless tobacco. The treatment is surgical resection. Radiotherapy is not indicated, as up to 30% treated with radiation become highly aggressive within six months.
(12 Dec 1998)
V-2 carcinoma <tumour> A transplantable, highly malignant carcinoma of experimental animals that developed as a result of malignant change in a virus-induced papilloma of a domestic rabbit.
(05 Mar 2000)
gallbladder carcinoma <radiology> Females (80%), peak age 60 - 70 years of age, associated with, gallstones (60-90%), porcelain gall bladder
(12 Dec 1998)
gastric carcinoma <radiology> 3rd most common GI malignancy (after colorectal and pancreas), 95% adenocarcinoma (rarely squamous cell or adenoacanthoma), predisposing factors: pernicious anaemia (2X risk), chronic atrophic gastritis, adenomatous and villous polyp (7-27% are malignant), gastrojejunostomy types: polypoid / fungating, ulcerating / penetrating (70%), infiltrating / scirrous = linitis plastica, increase in fibrous tissue; aperistalsis; rigidity, superficial spreading carcinoma, confined to mucosa/submucosa; 95% 5-year survival, patch of nodularity; little loss of elasticity location: 60% lesser curvature, 30% GE junction, 10% greater curvature probability of malignancy of an ulcer: fundus 90%, greater curvature 70%, lesser curvature 10-15%
(12 Dec 1998)
papillary carcinoma <tumour> A malignant neoplasm characterised by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 11
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 11
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 11
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 11
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 11
ÅëÇÕ°Ë»ö ¿Ï·á